CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The EBOVAC3 project focuses on advancing a candidate vaccine regimen against Ebola virus disease. It aims to support clinical and manufacturing activities necessary for the vaccine's licensure in Europe and the United States, targeting vulnerable populations including the elderly and HIV-infected individuals.
The overall aim of EBOVAC3 is to support an essential part of remaining clinical and manufacturing activities required for licensure in the European Union (EU) and the United States (US) of a candidate heterologous prime-boost prophylactic vaccine regimen against Ebola virus disease that is under development at Janssen Vaccines & Prevention B.V.
The intended target indication is defined as: “A prime-boost regimen with Ad26.ZEBOV as prime vaccine and MVA-BN®-Filo as boost vaccine indicated for th…
LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE ROYAL CHARTER
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Janssen Vaccines (f.k.a. Crucell Holland B.V.)
Netherlands, Leiden
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
France, Bordeaux
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
France, Talence
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
